| A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults (NCT07456059) | Edgewise Therapeutics, Inc. | 2026-03-10 |
| A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment (NCT07324616) | Edgewise Therapeutics, Inc. | 2026-01-26 |
| A Study of EDG-15400 in Healthy Adults (NCT07177066) | Edgewise Therapeutics, Inc. | 2025-08-20 |
| A Study to Evaluate EDG-7500 in People With Renal Impairment (NCT07034768) | Edgewise Therapeutics, Inc. | 2025-07-22 |
| A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers (NCT06916897) | Edgewise Therapeutics, Inc. | 2025-01-08 |
| A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500 (NCT06738836) | Edgewise Therapeutics, Inc. | 2024-12-03 |
| A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM) (NCT06347159) | Edgewise Therapeutics, Inc. | 2024-04-11 |
| Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy (NCT06066580) | Edgewise Therapeutics, Inc. | 2023-11-02 |
| A Study of EDG-7500 in Healthy Adults (NCT06011317) | Edgewise Therapeutics, Inc. | 2023-08-14 |
| Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers (NCT05730842) | Edgewise Therapeutics, Inc. | 2023-01-12 |
| Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) (NCT05291091) | Edgewise Therapeutics, Inc. | 2022-11-10 |
| A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) (NCT05540860) | Edgewise Therapeutics, Inc. | 2022-10-24 |
| A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling (NCT05492734) | Edgewise Therapeutics, Inc. | 2022-08-12 |
| A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy (NCT05160415) | Edgewise Therapeutics, Inc. | 2021-12-28 |